4-Aminopyridine ameliorates relapsing remitting experimental autoimmune encephalomyelitis in SJL/J mice

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
• Current treatments for MS symptoms are limited, particularly for the active phases of the disease.
• 4-aminopyridine (4-AP) is a potassium channel blocker used for symptomatic relief in chronic MS.

Purpose of the Study:

• To investigate the therapeutic effects of 4-aminopyridine (4-AP) on experimental autoimmune encephalomyelitis (EAE) models.
• To determine if 4-AP can ameliorate disease progression in chronic and relapsing-remitting forms of EAE.
• To explore the underlying immunological mechanisms of 4-AP's action in EAE.

Main Methods:

• Administration of 4-aminopyridine (4-AP) to mice with chronic EAE (chEAE) and relapsing-remitting EAE (rrEAE).
• Clinical scoring and pathological assessment of EAE severity in treated and control groups.
• Analysis of glial fibrillary acidic protein (GFAP) expression and T-cell responses (proliferation and cytokine polarization) in recall assays.

Main Results:

• 4-AP showed no significant effect on the chronic EAE model (chEAE).
• 4-AP significantly ameliorated disease severity in the relapsing-remitting EAE model (rrEAE), especially during the relapsing phase.
• Pathological examination confirmed disease amelioration, with reduced glial fibrillary acidic protein expression in 4-AP treated mice. T-cell proliferation was unaffected, but Th1/Th17 polarization was attenuated.

Conclusions:

• 4-AP demonstrates therapeutic potential in the active, relapsing phase of autoimmune neuroinflammation, distinct from its current use in chronic MS.
• The mechanism may involve modulation of glial activation and T-helper cell polarization, rather than direct inhibition of T-cell proliferation.
• These findings support consideration of 4-AP for treating active phases of multiple sclerosis.